The Science Behind
Restoring Mitochondrial Function

Exploiting Cancer’s Vulnerabilities With a Dual-Action Therapy

Cryton’s dual-action therapy is grounded in the principle that mitochondrial health dictates cellular fate. In healthy tissue, mitochondria efficiently regulate energy, signaling, stability and more. Cancer cells, however, are defined by severe mitochondrial dysfunction, forcing them to rely on fragile, compensatory pathways like glycolysis (the Warburg Effect) to survive.

Similarly, chronic immune responses against cancer can strain mitochondrial function in immune cells. This leads to immune exhaustion and reduced anti-tumor activity.

Cryton’s therapy seeks to address both vulnerabilities simultaneously, restoring mitochondrial function in both tumor and immune cells.

Unified Anti-Tumor Activity

Cryton’s proprietary small molecules target a critical metabolic checkpoint that governs mitochondrial function.

By activating a key enzyme shared by both tumor and immune cells, our therapy stabilizes and restores regulated mitochondrial function, unlocking a powerful, dual-action response:

Direct Tumor Killing
Restoring mitochondrial function forces cancer cells into rapid metabolic reprogramming. This creates severe mitochondrial stress, directly triggering immunogenic tumor death

.

Immune-Mediated Killing:
Activating the same metabolic pathway in CD8 T cells stabilizes their mitochondria and restores functional capacity. This reinvigorates exhausted immune cells to drive sustained anti-tumor activity

Pipeline

Target Class
Small Molecule

Indication
Solid Tumors

Molecule
Undisclosed

Program
CB-101

Discovery



Lead Optimization



Preclinical

R

Phase I/II

R

Phase III

R